Radio and PodcastLive Radio & PodcastsOpening Radio and Podcast...
Radio and PodcastLive Radio & PodcastsFetching podcast shows and categories...
Radio and PodcastLive Radio & PodcastsFetching podcast episodes...
This podcast series provides important up-to-the-minute information on MDS including diagnosis, treatment and clinical research.The explosion of information on MDS forces us to seek novel, a...
Dr. Moshe Mittelman is hosting the world-leading expert Dr. Michael Savona and they have an attractive conversation on several mechanisms in...
Prof. Uwe Platzbecker from Leipzig and Prof. Moshe Mittelman from Tel-Aviv in an interesting conversation on the various available therapeut...
Prof. Nicolaus Kröger from Hamburg and Prof. Moshe Mittelman from Tel-Aviv, in a stimulating conversation on the various therapeutic modalit...
Dr. Nicolaos Papadantonakis from Emory Atlanta and Dr. Moshe Mittelman from Tel-Aviv, describe several updated abstracts from 2023 ASH with...
Drs Nikolaos Papadantonakis of Emory, Atlanta, US, and Moshe Mittelman, Tel-Aviv, Israel, discuss trials presented in American Society of He...
Prof. Rena Buckstein from Toronto, and Prof. Moshe Mittelman from Tel-Aviv discuss issues related to RBC transfusions, the hemoglobin thresh...
Prof. Akiko Shimamura of Harvard Medical School, Boston, a world known expert of pediatric hematology discusses with Prof. Guillermo Sanz ,o...
Drs. Rafael Bejar (San Diego) and Moshe Mittelman (Tel Aviv) discuss several papers highlighting the role of genetics in MDS diagnosis, foll...
Drs. Moshe Mittelman, of The Tel Aviv Sourasky Medical Center, and Drorit Merkel, of the Sheba Medical Center, both from Tel Aviv University...
Chien Aza – Pembro - BJH The combination of azacitidine and pembrolizumab may be a potential effective regimen for patients with higher-risk...
We will discuss the addition of venetoclax to hypomethylating agents in the treatment of advanced myeloid neoplasms, especially higher-risk...
PAPER 1Authors: Vijenthira A. et al. (Princess Margaret, Toronto)Title: Outcomes of patients with hematologic malignancies and COVID-19: a s...
Bernard E et al: In the first presented study, Dr. Elza Bernard and colleagues deliver an important lesson about the high-risk mutation TP53...